RFID to Fight Drug Counterfeiting at The RFID Weblog

The U.S. Food and Drug Administration (FDA) is backing RFID as a way to stamp out prescription drug counterfeiting. RFID tracking technology would create an electronic pedigree that follows the drug from its manufacture to the point of dispensing. Accenture has been tapped to be the RFID program manager for a group of drug manufacturers, Distributors and retailers in this effort. The FDA issued a report on combating counterfeit drugs that [...] Read More


IBM RFID System to Fight Drug Counterfeiting at The RFID Weblog

Are you aware that one out of twelve prescription drugs get counterfeited each year and this is a real headache for the US Food and Drug Administration? The global supply chain of drugs is highly complicated in the sense that from the manufacturer and until it reaches the final user it changes hands at least ten times and it is very much possible that it could be counterfeited. FDA has [...] Read More


RFID Crystagram label: Hologram and RFID comes together to fight counterfeiting at The RFID Weblog

The RFID Crystagram label aims to put a stopper on something which has been hitting profits of companies in millions - counterfeiting. It has not only been affecting companies and consumers alike but every time counterfeiters are able to find out a novel method to bypass anti counterfeiting measures. Now it seems this may become difficult to pursue further. RFID Crystagram label is a combination of holographic image and 2.4 [...] Read More


Tuberculosis Drug Candidate SQ109 Granted Orphan Drug Status at The Biotech Weblog

The U.S. Food and Drug Administration and the European Medicines Agency has granted "orphan drug" status to SQ109, an antimicrobial agent against drug-resistant tuberculosis jointly developed by the National Institute of Allergy and Infectious Diseases (NIAID) and biotech company Sequella, Inc. This orphan designation will help accelerate clinical testing of SQ109, which promises simple and more effective treatment regimen than current methods which require six to nine months of treatment. SQ109 [...] Read More


Dangers in New Drug Policy at Eagle Par Birdie

There was more than a little confusion when European Tour players gathered this week for a meeting. The confusion surrounded some perceived discrepancies in the drug lists between the PGA and European PGA tours. Two of the players - Ian Poulter and Paul Casey - questioned why the PGA list contained three permissible drugs to treat erectile dysfunction while the European list allowed only one. [...] Read More